TSE:4568Pharmaceuticals
A Look At Daiichi Sankyo (TSE:4568) Valuation After ENHERTU’s Latest Oncology Approvals
Daiichi Sankyo Company (TSE:4568) is back in focus after China approved ENHERTU as the first HER2 directed antibody drug conjugate for second line HER2 positive metastatic gastric cancer. This development spotlights its oncology pipeline alongside recent European regulatory progress.
See our latest analysis for Daiichi Sankyo Company.
Despite the positive headlines around ENHERTU and recent corporate updates, Daiichi Sankyo Company's share price has had a weak patch, with a 30 day share price...